STI | Men (N=204) | Women (N=187) | ||||
SOC (n=103) | NIT (n=101) | p Value | SOC (n=94) | NIT (n=93) | p Value | |
Gonorrhoea | ||||||
Declined testing | 0 (–) | 0 (–) | – | 1 (1%) | 0 (–) | 0.3 |
Agreed testing | 103 (100%) | 101 (100%) | 93 (99%) | 93 (100%) | ||
Negative | 103 (100%) | 100 (99%) | 0.3 | 92 (99%) | 76 (82%) | 0.001 |
Positive | 0 (–) | 1 (1%) | 0 (–) | 6 (6%) | ||
Inhibitory | 0 (–) | 0 (–) | 1 (1%) | 10 (11%) | ||
Indeterminate | 0 (–) | 0 (–) | 0 (–) | 1 (1%) | ||
Chlamydia | ||||||
Declined testing | 0 (–) | 0 (–) | – | 0 (–) | 0 (–) | |
Agreed testing | 103 (100%) | 101 (100%) | 94 (100%) | 93 (100%) | ||
Negative | 96 (93%) | 93 (92%) | 0.8 | 83 (88%) | 78 (84%) | 0.1 |
Positive | 7 (7%) | 8 (8%) | 9 (10%) | 8 (9%) | ||
Inhibitory | 0 (–) | 0 (–) | 1 (1%) | 7 (7%) | ||
Equivocal | – | – | 1 (1%) | 0 (–) | ||
HIV | ||||||
Declined testing | 21 (20%) | 13 (13%) | 0.1 | 17 (18%) | 5 (5%) | 0.007 |
Agreed testing | 82 (80%) | 88 (87%) | 77 (82%) | 88 (95%) | ||
Negative | 81 (99%) | 88 (100%) | 0.3 | 75 (98%) | 86 (98%) | 0.3 |
Positive | 0 (–) | 0 (–) | 1 (1%) | 0 (–) | ||
Status known | – | – | 1 (1%) | 0 (–) | ||
Missing | 1 (1%) | 0 (–) | 0 (–) | 2 (2%) | ||
Syphilis | ||||||
Declined testing | 14 (14%) | 7 (7%) | 0.1 | 12 (13%) | 3 (3%) | 0.02 |
Agreed testing | 89 (86%) | 94 (93%) | 82 (87%) | 90 (97%) | ||
Negative | 87 (98%) | 93 (99%) | 0.2 | 80 (98%) | 87 (97%) | 0.4 |
Positive | 0 (–) | 1 (1%) | 0 (–) | 0 (–) | ||
Status known | – | – | 1 (1%) | 0 (–) | ||
Missing | 2 (2%) | 0 (–) | 1 (1%) | 3 (3%) | ||
T vaginalis | ||||||
Negative | – | – | 89 (95%) | 1 (1%) | ||
Positive | – | – | 2 (2%) | 1 (1%) | ||
Missing | – | – | 3 (3%) | 91 (98%) | ||
Other | ||||||
Bacterial vaginosis | – | – | 2 (2%) | 0 (–) | ||
Candida | – | – | 2 (2%) | 0 (–) | ||
Warts | – | – | 1 (1%) | 0 (–) | ||
Non-specific urethritis | 4 (4%) | 0 (–) | – | – |
Testing of T vaginalis was not performed in the non-invasive testing (NIT) arm patients.
SOC, standard of care; STI, sexually transmitted infection.